AICHI, Japan--(BUSINESS WIRE)--RaQualia Pharma Inc. (RaQualia)(JASDAQ:4579)(ISIN:JP3967150008) today announced the signing of a license agreement with CJ CheilJedang Co. (CJ), granting CJ exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 Partial Agonist (RQ-00000010) in Korea, China, Taiwan, India and Southeast Asia.
